Last updated: 2026-09-05 12:22:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
REGENXBIO Inc. (RGNX) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $8.94, with a market capitalization of $633.73M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $5.46 to $16.19. This page covers its latest market performance, valuation, price trends and company information.
$633.73M | |
$9.09 | |
$85.10 | |
$5.04 | |
$9.20 | |
936.12K | |
-- | |
-- | |
$16.19 | |
$5.46 | |
-- | |
-- |
REGENXBIO Inc. (RGNX) last closed at $9.20 as of 2026-09-04 23:56:00, unchanged from the previous close of $9.20.
During the latest regular trading session, RGNX traded between $5.04 and $85.10, with a volume of 936.12K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, REGENXBIO Inc. (RGNX) moved from $9.50 to $8.94, representing a decline of 5.95% ($0.56).
The stock traded between $8.86 and $9.27 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.12 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 32.4%
RGNX is currently trading at $8.94, placing it 32.4% of the way from its 52-week low of $5.46 to its 52-week high of $16.19. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 371 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of REGENXBIO Inc. (RGNX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.